An immunotherapy directed towards antigens within the NP protein of COVID-19 is being developed by CEL-SCI Corporation for the treatment of coronavirus infection. The therapeutic is being developed using the company's proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology platform which will use conserved regions of coronavirus proteins to stimulate protective cell mediated cytolytic T cell responses and reduce viral load. L.E.A.P.S.™ generated therapeutics exhibit both antiviral and anti-inflammatory properties. The COVID-19 peptide is believed to not only arrest the progression of the virus but also prevent tissue damage from inflammation resulting from lung infection by the virus. Early research is ongoing in the US.
In March 2020, CEL-SCI Corporation entered into a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology for the development of LEAPS COVID-19 immunotherapy. The collaboration will commence with pre-clinical studies based on the experiments previously conducted with LEAPS immunotherapy in collaboration with the National Institutes for Allergies and Infectious Diseases (NIAID) against another respiratory virus, H1N1, involved in the 2009 H1N1 flu pandemic. 
L.E.A.P.S.™ is protected by patents in the United States issued in February 2006, April 2007, August 2007, January 2019 and March 2019. The LEAPS patents, which expire in 2021, 2022, 2021 and three in 2032, respectively, include overlapping claims, with composition of both matter (new chemical entity), process and methods-of-use, to maximize and extend the coverage in their current format    .
In October 2017, a patent was issued in Europe for L.E.A.P.S.™ , which expires in 2029  .
CEL-SCI Corporation has four patent applications pending in the United States and one in Europe for L.E.A.P.S.™, which, if issued, would extend protection through 2034, subject to any potential patent term extensions  .